Older Age Threshold for Oxaliplatin Benefit in Stage II to III Colorectal Cancer

Is there an optimal age threshold for a survival benefit of adding oxaliplatin to fluoropyrimidine-based adjuvant chemotherapy among older patients with stage II to III colorectal cancer?In this cohort study of 8561 Korean patients, oxaliplatin was associated with improved overall survival among patients aged 70 years or younger with stage III disease but not among those older than 70 years or those with stage II disease.The findings suggest that oxaliplatin may benefit patients aged 70 years or younger with stage III colorectal cancer, while its use in patients aged older than 70 years and those with stage II disease warrants reconsideration.

Corresponding Authors: Seogsong Jeong, MD, PhD, Department of Biomedical Informatics, Korea University College of Medicine, 145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea (seogsongjeong@korea.ac.kr); Sanghee Kang, MD, PhD, Department of Surgery, Korea University Guro Hospital, Korea University College of Medicine, Seoul, 148 Gurodong-ro Guro-gu, Seoul 08308, Korea (kasaha1@korea.ac.kr).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.